Navigation Links
ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis
Date:9/21/2008

fically inhibit the production of VLA-4 could significantly reduce disease activity in RRMS patients as early as 8 weeks. The level of efficacy achieved by ATL/TV1102 is very promising particularly when considering the short duration of dosing within the trial. As an antisense drug ATL/TV1102 will have a different, potentially preferable, safety profile to other drugs that target VLA-4 and therefore presents an exciting future treatment option for RRMS patients."

Mark Diamond, Chief Executive Officer of Antisense Therapeutics, said, "We are delighted to have our ATL/TV1102 Phase IIa trial results presented at such an important scientific meeting on MS. The development of ATL/TV1102 as an MS treatment continues with our partner Teva Pharmaceutical Industries (Teva) and we look forward to the prospect of Teva reporting on ATL/TV1102's future clinical progress. Importantly, the demonstration of significant disease activity with ATL/TV1102 in MS points to the potential of ATL/TV1102 in other disease settings such as autoimmune, inflammation and cancer. It also provides important validation for the application of second-generation antisense drugs outside of cardiovascular and metabolic diseases such as high cholesterol and diabetes where there has been success to date. We believe our results provide important substantiation for the broader clinical application of the second-generation technology."

"We are very encouraged by the data. Not only do they represent promising results for patients with MS, but they also evidence the significant progress we are making in demonstrating the effectiveness, efficiency and the breadth of opportunity of our antisense platform. It's another disease and another tissue where we have great proof-of-concept for antisense drugs," said Stanley Crooke, M.D., Ph.D., Chairman and Chief Executive Officer of Isis. "ATL/TV1102 and ATL's strategic relationship with Teva to move the drug forward further validates our business strategy.
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.; Antisense Therapeutics Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... May 24, 2013 China Biologic Products, Inc. ... fully integrated plasma-based biopharmaceutical company in China ... learned from a public announcement issued by Shanghai RAAS ... listed on Shenzhen Stock Exchange, that on May 21, ... ("Ms. Chan"), one of the shareholders of the Company, ...
(Date:5/24/2013)... , May 24, 2013 In accordance with Rule ... Rule 14e-1 of the United States Exchange Act, Echo Pharma ... offer for Elan Corporation (NYSE: ELN). Background ... Pharma") made an offer for the entire of the issued ... ("Elan") (the "Original Offer").  On 20 May ...
(Date:5/24/2013)... -- The potential of the pulmonary route ... agents has been receiving undeniable attention with the recent ... The crucial formulation considerations for orally inhaled products together ... role in the efficiency of pulmonary delivery, and great ... formulation techniques and devices in recent years. ...
Breaking Medicine Technology:China Biologic Comments on the Proposed Shanghai RAAS Transaction 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 3China Biologic Comments on the Proposed Shanghai RAAS Transaction 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2
... Mass. and SYDNEY, April 15, 2011 HeartWare ... HIN), a leading innovator of less invasive, miniaturized ... of advanced heart failure, today announced the presentation ... heart transplantation (BTT) study, ADVANCE, showing 180-day survival, ...
... Nanotechnologies, Inc. ("Shrink") (OTCBB:INKN), an innovative high technology ... Shrink,s Cell Align™ cell culturing and tissue engineering ... substrate has been filed with the US Patent ... a micro-fabricated substrate with non-periodic (or random) linear ...
Cached Medicine Technology:HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 2HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 3HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 4HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 5Shrink Nanotechnologies Announces That Critical Cell Align Tissue Engineering Platform Patent as Well as IP on a Novel Immunoassay Substrate Material Has Been Filed With the USPTO 2Shrink Nanotechnologies Announces That Critical Cell Align Tissue Engineering Platform Patent as Well as IP on a Novel Immunoassay Substrate Material Has Been Filed With the USPTO 3
(Date:5/24/2013)... Los Angeles, CA (PRWEB) May 24, 2013 ... “Looking Good on Facebook: Social Media Leads to Spikes in ... indicate that there is a growing prevalence of facial ... utilize social media. These people have become keenly aware of ... profiles on sites such as Facebook, Google and even Skype's ...
(Date:5/24/2013)... FRIDAY, May 24 (HealthDay News) -- The number ... units after spending time in an emergency room ... new research. The study, conducted by researchers ... Health and Health Services in Washington, D.C., found ... room on average before being admitted to the ...
(Date:5/24/2013)... fractional flow reserve (FFR) using pressure wire assessment ... leads to significant changes in the management of ... a study reported at EuroPCR 2013. , The ... strategy at coronary angiography for diagnosis of chest ... assessment of FFR in all the main coronary ...
(Date:5/24/2013)... Ore. A new discovery at Oregon Health & ... body effectively reacts when infected with the highly evasive ... researchers has been utilizing this unique approach to develop ... shown promising results in animal studies. This latest research ... edition of the journal Science . , ...
(Date:5/24/2013)... CBT News.com recently announced the addition of Tom Gonter as ... news organization with 12 years experience in online and social ... that’s so forward-thinking in their approach,” says Gonter. “CBT News ... on the rise.” , Atlanta born and raised, Gonter began ... at Cycle News and Boating World. He made the move ...
Breaking Medicine News(10 mins):Health News:Facebook and Google – Is Social Media Driving Demand for Plastic Surgery? 2Health News:Sharp Rise in ICU Admissions From U.S. Emergency Rooms 2Health News:Diagnostic coronary angiography: Functional flow reserve changes decisions in 25 percent of cases 2Health News:OHSU research highlights promising strategy to help vaccines outsmart HIV 2
... , ... , an Australian start-up, has been selected to showcase its revolutionary service for managing ... ... Global financial innovation conference, Finovate, has selected Controlabill to showcase its revolutionary service for ...
... ... accreditation by COLA, a national healthcare accreditation organization. , ... (PRWEB) March 24, 2010 -- This year, US ... performance in quality patient testing and overall exemplary application of the principles of laboratory ...
... The ... But, what most of us don’t know is that chemotherapy wreaks havoc on our teeth ... with your dental health while undergoing chemotherapy and radiation. , ... (PRWEB) March 24, 2010 -- Steven McConnell - a Marin ...
... , ... will be presenting three sessions in April to increase awareness in the U.S. about the ... can increase early detection and prevention. , ... New York, NY (Vocus) March 24, 2010 -- The Bella Moss Foundation, a ...
... , ... Many of seniors, greatest fears are tied to the loss ... to remain active because of conditions that often accompany aging. But staying ... Paul Hogan. In response to mounting research that underscores the mental and ...
... ... ... -- At just over 18 pounds and with a sound level of only 58 dBA, ... quieter than its battery-operated competitors. Powered by a lithium ion battery with 30 minutes of ...
Cached Medicine News:Health News:Global Financial Innovations Conference Chooses Australian Start Up, Controlabill 2Health News:US Wellness, Inc. Receives National Recognition for Laboratory Excellence 2Health News:Recommended Dental Care for Chemotherapy Patients -- Advice from Steven McConnell, DDS 2Health News:Recommended Dental Care for Chemotherapy Patients -- Advice from Steven McConnell, DDS 3Health News:The Bella Moss Foundation Announces U.S. Tour to Raise Awareness of MRSA in Pets 2Health News:The Bella Moss Foundation Announces U.S. Tour to Raise Awareness of MRSA in Pets 3Health News:Senior Fear Factors: What Aging Americans Fear Most 2Health News:Senior Fear Factors: What Aging Americans Fear Most 3Health News:Advance Introduces the Adgility™ XPB Battery Backpack Vacuum – the Lightest in the Industry, 2
This set offers the full range of Keeler magnifiers and telescopes....
... Featuring up to ... allows examination in the ... sections plus the option ... for corneal transillumination., ,Filters ...
... image guided surgery system offers full-featured ... design and use. It provides unparalleled ... localize critical anatomy and plan optimal ... surgeons an easy-to-use, technologically advanced approach ...
Comes complete with its own case. A unique integrated design with no need for two separate bars., ,Optical surfaces are recessed for optimum protection. Extensive prism power 1,2,3,4,6,8,10,15,20...
Medicine Products: